Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia

Abstract Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent monotherapy. However, little is known about the performa...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Ian M. Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Nolan A. Wages, Steven Grant, Keri R. Maher
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2023-05-01
Sarja:	eJHaem
Aiheet:	acute leukemia AML BCL2 chemotherapy clinical research malignant hematology
Linkit:	https://doi.org/10.1002/jha2.663
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!